Exploring the potential of circular RNA
Vaccine Insights 2023; 2(1), 5–8
As the leader of a research group focused on developing novel, clinically relevant delivery technologies for nucleic acid-based therapies, I saw first-hand how the COVID pandemic accelerated manufacturing and scale-up processes and regulatory frameworks for mRNA-based drugs. The pandemic catalyzed academic and industry research and development (R&D) activities in the mRNA field, as well as in the lipid nanoparticle (LNP) technology used to deliver the vaccines. However, there is still huge scope for improvement.